The Lumify with Reacts handheld tele-ultrasound solution, from Amsterdam-based Royal Philips, is now commercially available in Japan. Philips has received clearance from Japan’s healthcare authority to introduce the ultrasound solution for compatible handheld devices. Launched in Japan with a novel subscription model unique in the industry, Philips’ tele-ultrasound solution aims to make high-quality portable ultrasound available almost everywhere in the country.

Japan’s declining birthrate and aging population makes the need for medical diagnostic equipment that can adapt to these changing demographics more relevant than ever. The portability of Lumify brings a powerful portable diagnostic solution to care professionals in the hospital, enabling them to use ultrasound imaging for bedside diagnosis and to monitor medical conditions. Additionally, Lumify can be easily taken to community settings at the point of care, helping to reduce the need for elderly people to travel to hospitals in Japan’s larger cities.

“By bringing diagnostic insight to the point of care, Lumify is a great example of how Philips is supporting providers to deliver on the ambition of the ‘quadruple aim’ in healthcare: better health outcomes, an improved experience for patients and staff, and a lower cost of care,” says Matthijs Groot Wassink, general manager for access and obstetric ultrasound at Philips. “Its transducer connects to a smart device such as a tablet, making it a compact and highly durable solution. In addition, by utilizing Philips’ Lumify with Reacts capability, real-time ultrasound images can be shared between medical staff involved in collaboration during imaging procedures.”

Handheld and portable ultrasound solutions in particular have become valuable tools for clinicians treating COVID-19 patients due to their imaging capabilities, portability, and ease of disinfection. Philips ultrasound solutions have been approved in various markets for the management of COVID-19-related lung and cardiac complications, including in Australia, Brazil, Canada, the EU, New Zealand, and the United States.

For more information, visit Royal Philips